ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage ...

AUSTIN - ADAR1 Capital Management, LLC, the major shareholder of Keros Therapeutics (NASDAQ:KROS), has urged the biotechnology firm to disclose the results of its strategic review before its upcoming ...

Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is ...

LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage ...

Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros ...

AUSTIN - ADAR1 Capital Management, LLC, the major shareholder of Keros Therapeutics (NASDAQ:KROS), has urged the biotechnology firm to disclose the results of its strategic review before its ...

"KER-065 appears promising and may have the potential to benefit a broad spectrum of patients with DMD, from young ambulatory boys to older, non-ambulatory individuals.” - Liesbeth De Waele, MD, ...

May 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...